Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium Respimat vs Salmeterol and Placebo in Moderate Persistent Asthma
NCT01172821Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of tiotropium in asthma (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Peak FEV1 Within 3 Hours Post-dose Response, Trough FEV1 Response at 24 weeks and 1 more. Started Aug 2010; status: completed.
02
Drugs
tiotropium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01172821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172821.